ArticleForensic science, medicine, and pathology2026
Suicide by flecainide: a case report and review of the literature.
Article in Forensic science, medicine, and pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeFlecainide is a prescription drug used to treat or prevent various types of arrhythmias by decreasing conduction velocity. Despite its therapeutic utility, flecainide has a narrow safety margin and potential for fatal toxicity. This study presents a forensic case of fatal flecainide intoxication and investigates the role of pharmacogenetics in drug metabolism and toxicity.
methodsA 27-year-old medical doctor, prescribed flecainide, was found deceased. Postmortem examination included histological and toxicological analyses of blood and urine samples, with flecainide quantification by a validated method. CYP2D6 and CYP3A5 were genotyped to check for variants of the respective drug-metabolizing enzymes. A literature review of fatal and non-fatal flecainide intoxication is also presented.
resultsFlecainide concentrations measured 3.411 mg/l and 2.962 mg/l in central and peripheral blood, respectively. Pharmacogenetic analysis identified a CYP3A5 *3/*3 poor metabolizer genotype, likely contributing to reduced drug clearance and increased toxicity. Histology revealed mild coronary stenosis and signs consistent with cardiogenic shock. The death was deemed a suicide, possibly facilitated by abnormal metabolic phenotype in a mildly compromised cardiac substrate.
conclusionsThis case highlights the complexities in diagnosing lethal flecainide intoxication, particularly considering postmortem concentration variability and individual metabolic differences. Integrating pharmacogenetic data enhances interpretation of toxicological findings and may guide personalized therapeutic strategies to mitigate risk. Further research is warranted to clarify genetic influences on flecainide toxicity.
Indexed as
Identifiers
41793576What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.